Document:

Exhibit 10.1

 

Amended
and Restated Master Services Agreement

 

This
Amended and Restated Master Services Agreement (the “Agreement”), dated as of May 1, 2018 (the “Effective
Date”), is between Medpace, Inc., an Ohio Corporation with a principal place of business at 5375 Medpace Way, Cincinnati,
OH 45227, (“Medpace”) and Ritter Pharmaceuticals, Inc., a Delaware Corporation with a principal place of business
at 1880 Century Park East, Suite #1000, Los Angeles, CA 90067, (“Sponsor”). Medpace and Sponsor are sometimes referred
to herein individually as a “Party” and together as the “Parties”.

 

RECITALS:

 

WHEREAS,
Sponsor is in the business of developing and obtaining regulatory approval of the marketing and sale of pharmaceutical products;
and

 

WHEREAS,
Medpace is engaged in the business of providing services related to the design and execution of clinical development programs
involving drugs, biologics, and medical devices through engagement by its clients, the sponsors of clinical development programs,
to perform such services; and

 

WHEREAS,
Sponsor desires to engage Medpace to perform certain services (“Services”) as set forth hereinafter in connection
with certain clinical trials (each, a “Study” or collectively, the “Studies”), all in accordance with
and subject to the terms of this Agreement;

 

WHEREAS,
Medpace and Sponsor have entered into that certain Master Services Agreement, dated August 30, 2016; and

 

WHEREAS,
Medpace and Sponsor have agreed to enter into this Amended and Restated Master Services Agreement, and upon execution of this
Agreement, the Master Services Agreement, dated August 30, 2016, shall be deemed terminated and superseded.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants and conditions hereinafter set forth, the Parties agree
as follows:

 

	1.	PROJECT
    SPECIFICATIONS

 

	 	A.	Medpace
    hereby agrees to perform Services for Sponsor from time to time in accordance with the terms of this Agreement. For the sake
    of clarity, the Services contemplated under this Agreement shall be provided on a non-exclusive basis and Sponsor reserves
    the right to undertake all work on its own behalf or to obtain similar services from a third party. Sponsor shall not be obligated
    to purchase any minimum or specific volume or dollar amount of Services hereunder.
	 	 	 
	 	B.	The
    precise Services to be performed by Medpace shall be mutually agreed upon by the Parties in writing and set forth in one or
    more task orders (each a “Task Order”), a form of which is attached hereto as Exhibit A. Each Task Order shall
    be signed by an authorized representative of each Party and shall include detailed information concerning a given project,
    including a description of the specific Services to be provided (“Scope of Work”), project milestones and target
    completion dates (“Project Schedule”), a detailed budget (“Project Budget”), and a schedule of payments
    related to the Project Schedule and the Project Budget (“Payment Schedule”). The Parties acknowledge and agree
    that Medpace may provide Services directly or through an Affiliate, as defined below. Each Task Order shall contain a Transfer
    of Obligations list (“Transfer of Obligations”) in conjunction with the relevant Task Order and consistent with
    the regulations set forth in 21 C.F.R. Section 312, Subpart D (Responsibilities of Sponsors and Investigators). Any responsibilities
    not specifically transferred to Medpace in the Transfer of Obligations shall remain the regulatory responsibility of Sponsor.
    Each Party shall provide such reasonable cooperation as the other may request in connection with the other Party’s compliance
    with the applicable provisions of Part 312.

 

    	 	 	1 | Page

    	 

    

 

	 	C.	Unless
    otherwise stated in the applicable Task Order, the Services will be conducted in compliance with Medpace Standard Operating
    Procedures (“SOPs”) and Policies.
	 	 	 
	 	D.	From
    time to time, Sponsor may wish to enter into a Task Order with a Medpace Affiliate for Services under this Agreement (“Affiliate
    Task Order”), and such Medpace Affiliate may wish enter into the Affiliate Task Order with Sponsor. Any such Affiliate
    Task Order must be in writing and signed by the parties to the Affiliate Task Order, and each signatory to an Affiliate Task
    Order is solely responsible for all obligations it undertakes under the Affiliate Task Order. For the purposes of a particular
    Affiliate Task Order, the Affiliate signing such Affiliate Task Order will be substituted for Medpace everywhere it appears
    in this Agreement, and the term “Affiliate Task Order” will be substituted for Task Order everywhere it appears
    in this Agreement. Medpace shall be responsible for the compliance of its Affiliate with all of the terms and conditions applicable
    to Services performed under each Affiliate Task Order.
	 	 	 
	 	E.	As
    used herein, “Affiliate” means in relation to a Party, any entity, directly or indirectly, controlling such Party,
    controlled by such Party, or under common control with such Party. For purposes of this Agreement, “control”,
    whether used as a noun or a verb, means the possession, directly or indirectly, of the power to affirmatively direct, or affirmatively
    cause the direction of, the management and policies of an entity, whether through the ownership of voting securities, by contract,
    or otherwise.
	 	 	 
	 	F.	Pre-funded
    Vendors:

 

	 	i.	As
    part of the Services and as an accommodation to Sponsor, Medpace may contract with third parties for the provision of services
    not customarily performed or provided by Medpace; provided, however, Medpace has obtained Sponsor’s prior written consent
    to use such third parties (“Pre-funded Vendors”). The Parties acknowledge and agree that any third party paid
    with Pre-funded Expenses in connection with the performance of Services under this Agreement or any Task Order shall not be
    considered the agent, employee, or subcontractor of Medpace. Medpace shall provide to Sponsor any amounts that Medpace may
    recover from such Pre-funded Vendor as a result of any error or service failure on the part of such Pre-funded Vendor in connectionwith
    Services under this Agreement, less reasonable costs incurred by Medpace. Medpace shall use commercially reasonable efforts
    to add Sponsor as a third-party beneficiary to such contracts with Pre-funded Vendors (“Pre-funded Vendor Agreements”)
    to allow Sponsor to exercise and enforce similar rights as Medpace may have under its contract with any such Pre-funded Vendor,
    including without limitation the right to audit and inspect such Pre-funded Vendor’s financial affairs, facilities,
    processes and procedures. Medpace shall comply with and fully enforce all provisions of Pre-funded Vendor Agreements between
    Medpace and the relevant Pre-funded Vendor, to the extent such provisions affect any of Sponsor’s rights, and shall
    not amend, waive or settle any dispute with respect to (or permit any amendment or waiver of or settlement of any dispute
    with respect to) any provision of such Pre-funded Vendor Agreement that affects any of Sponsor’s rights hereunder without
    the prior written consent of Sponsor.

 

    	 	 	2 | Page

    	 

    

 

	 	ii.	Medpace
    may engage with and coordinate the services of such Pre-funded Vendors and make payments after receipt of sufficient funds
    from Sponsor that were pre-approved in writing by Sponsor (“Pre-funded Expenses”). If sufficient funds are not
    received from Sponsor, payments to Pre-funded Vendors may be delayed. Pre - funded Expenses may include but are not limited
    to third party advance payments for investigator meetings, vendors, Study Site (defined below) payments, and any payments
    to investigators, institutions, and site maintenance organizations for services performed that relate to a Study and pre-approved
    in writing by Sponsor. Medpace shall indemnify, defend and hold Sponsor harmless for all third party claims, suits, liabilities,
    damages and expenses (including attorneys’ fees and litigation costs) arising out of Medpace’s material failure
    or delay in making any such Pre-Funded Expense payments to Study Sites or Pre-funded Vendors; provided, however, that if Sponsor
    fails to provide to Medpace sufficient funding that was pre-approved in writing by Sponsor, Medpace shall have no obligation
    to indemnify Sponsor for claims resulting from Medpace’s failure or delay.

 

	 	G.	At
    all times during the term of this Agreement, the Parties shall comply, to the extent applicable, with all relevant federal
    and local laws statutes and regulations of any country or territory where the Study is being conducted and/or where the Study
    Site is located (“Applicable Laws”).

 

	 	i.	Applicable
    Laws in the United States shall include all applicable federal, state and local laws, statutes and regulations, including
    but not limited to the following federal statute and sections of the United States Code of Federal Regulations (“CFR”):

 

	 	(A)	21
    CFR Part 312- Investigational New Drug Application;
	 	 	 
	 	(B)	21
    CFR Part 50 - Protection of Human Subjects;
	 	 	 
	 	(C)	21
    CFR Part 54 - Financial Disclosure by Clinical Investigators;
	 	 	 
	 	(D)	21
    CFR Part 56 - Institutional Review Boards;
	 	 	 
	 	(E)	Health
    Information Portability and Accountability Act of 1996 (“HIPAA”) and any regulation and official guidelines (all
    as may be amended from time to time) promulgated under that Act;
	 	 	 
	 	(F)	Health
    Information Technology for Economic and Clinical Health Act (“HITECH”) and any regulation and official guidelines
    (all as may be amended from time to time) promulgated under that Act;

 

    	 	 	3 | Page

    	 

    

 

	 	(G)	United
    States Foreign Corrupt Practices Act, the U.S. Export Administration Act, the U.S. Anti-Boycott Regulations and other applicable
    anti-corruption statues;
	 	 	 
	 	(H)	World
    Medical Association Declaration of Helsinki entitled “Ethical Principles for Medical Research Involving Human Subjects”
    (2004 version); and
	 	 	 
	 	(I)	The
    United States Federal Food, Drug and Cosmetic Act, as amended.

 

	 	H.	In
    the event of any “Adverse Event” as such term is defined in 21 CFR 312.32, and to the extent such activities are
    included in an applicable Task Order, Medpace shall comply with the reporting procedure provided for in the applicable Study
    protocol and herein and to the extent included in a Task Order shall be responsible on behalf of Sponsor for collecting and
    submitting to Sponsor reports of adverse drug events and drug experiences as specified in the Study protocol, and all relevant
    adverse event information. Unless Sponsor notifies Medpace otherwise, serious adverse drug experience reports shall be, in
    all cases, forwarded within one (1) business day from Medpace to Sponsor. For each Study, Medpace will provide to Sponsor
    cumulative quarterly and annual serious adverse drug experience reports in an agreed upon format.
	 	 	 
	 	I.	Except
    as otherwise agreed by the Parties in writing, Sponsor is and at all times remains, in all geographical regions where the
    Study is being performed, the “Sponsor” or “Legal Representative” of the Study pursuant to Applicable
    Law.
	 	 	 
	 	J.	If
    requested pursuant to a Task Order, Medpace may assist Sponsor in identifying investigators and study sites (collectively,
    “Study Sites”) to perform the related Study and may facilitate the negotiation of clinical trial agreements (“Investigator
    Agreement”) between Investigators and Sponsor. If, pursuant to the applicable Task Order, Sponsor delegates to Medpace
    the negotiation of such Investigator Agreements as part of the Services, then Medpace agrees to comply with the Site Negotiation
    Plan (as defined below) provided by Sponsor and Medpace will work diligently to conclude Investigator Agreements with Study
    Sites in a timely manner, keeping in mind the Study timelines, including by zealously negotiating to conclusion any Study
    Site-initiated changes to Investigator Agreements within such parameters as Sponsor directs or permits, including the Site
    Negotiation Plan and any other Sponsor approved “fall-back” language provided by Sponsor to Medpace. Medpace shall
    not agree to any substantive changes or revisions to the Investigator Agreements outside of the Site Negotiation Plan or Sponsor
    approved fallback provisions without the prior written approval of Sponsor. For the sake of clarity, Medpace and Sponsor shall
    both be parties entering into the Investigator Agreements with the Study Sites, unless otherwise agreed to by the Parties.
    Unless the form of Investigator Agreement is mandated by regulation or local custom, Medpace shall provide its own Investigator
    Agreements template to Sponsor for review and approval. Sponsor shall have the right to approve all Investigator Agreement
    templates for use and all finalized Investigator Agreements prior to execution. Upon award of a Study, Sponsor shall provide
    Medpace with written instructions regarding negotiation parameters for the Investigator Agreements (the “Site Negotiation
    Plan”), which will be agreed to by the Parties at a later date. Where provided in the relevant Task Order, Medpace shall
    be responsible for negotiating clinical grants with each participating Study Site in accordance with the budget pre-approved
    in writing by Sponsor and set forth in the applicable Task Order. Sponsor shall have the right to approve in writing all finalized
    Study Site clinical grant budgets and Investigator Agreements prior to execution.

 

    	 	 	4 | Page

    	 

    

 

	2.	PROJECT
    SCHEDULE

 

	 	A.	Each
    Task Order shall contain project timelines, milestones or target dates for completion of a project or a portion thereof, and
    all such schedules shall be reasonable for the Services to be provided. In all events, the Parties shall comply with each
    Task Order.
	 	 	 
	 	B.	If
    at any time either Party anticipates a delay in meeting the timelines for a given Task Order as set forth in its Project Schedule,
    either due to changes to the Services requested by Sponsor, or other causes beyond the affected Party’s control and
    not due to such Party’s negligence or willful misconduct (for example, but without limitation, slower than anticipated
    patient enrollment), then the anticipating Party shall promptly notify the other Party, specifying the reason for the delay
    and the anticipated effect upon the timelines, milestones or other deliverables. The Parties may provide such notification
    during routine status updates or conference calls. The Party affected shall use all reasonable endeavors to eliminate or cure
    or overcome any such delays and to resume performance of its obligations with all possible speed.

 

	3.	CONTRACT
    AMENDMENTS

 

	 	A.	Any
    change in the details of a Task Order or the assumptions upon which the Task Order is based may require changes in the Project
    Budget, Payment Schedule or Project Schedule. Every such change shall require a written amendment to the Task Order (a “Contract
    Amendment”). Each Contract Amendment shall detail the requested changes to the applicable task, responsibility, duty,
    budget, timeline or other matter. The Contract Amendment will become effective upon the execution of the Contract Amendment
    by both Parties, and if applicable, will specify the period of time within which Medpace must implement the changes. Both
    Parties agree to act in good faith and promptly when considering a Contract Amendment requested by the other Party but neither
    Party is obligated to execute a Contract Amendment. No Contract Amendment shall become effective unless and until it is signed
    by both Parties. In the event that Sponsor requests that Medpace perform out-of-scope work prior to the execution of a Contract
    Amendment, Sponsor will provide Medpace with written authorization by a duly authorized senior officer of Sponsor to perform
    such additional Services and agrees to compensate Medpace for the provision of such additional Services in accordance with
    the written authorization. Medpace and Sponsor will work in good faith to execute a Contract Amendment including such additional
    Services.

 

    	 	 	5 | Page

    	 

    

 

	4.	PROJECT
    BUDGET, PAYMENT SCHEDULE, AND TERMS

 

	 	A.	Service
    Fees:

 

	 	i.	The
    Sponsor agrees to pay Medpace in accordance with the Project Budget and Payment Schedule for Services properly rendered pursuant
    to this Agreement and each Task Order.

 

	 	B.	Pass
    Through Costs:

 

	 	i.	The
    Sponsor agrees to reimburse Medpace for reasonable and necessary pass-through costs that were pre-approved in writing by Sponsor
    and incurred by Medpace in providing the Services in accordance with the relevant Task Order (“Pass-through Costs”).
    Pass-through Costs may include, but are not limited to, CRF printing costs, project-specific printing, shipping, copying and
    binding costs, telecommunication and data costs, travel costs, including subsistence and accommodation costs in compliance
    with the Medpace travel policy, literature search and article retrieval costs, translation costs, EC/regulatory fees, and
    pharmacy fees. All expenses billed to Sponsor by Medpace must be accompanied by appropriate documentary evidence, such as
    receipts or other documentation reasonably acceptable to Sponsor. The Parties acknowledge and agree that any third party paid
    with Pass-through Costs in connection with the performance of Services under this Agreement or any Task Order shall not be
    considered the agent, employee, or subcontract of Medpace.

 

	 	C.	Pre
    - funded Expenses:

 

	 	i.	The
    Parties will work to establish a process for payment of Pre-funded Expenses in the applicable Task Order which allows for
    timely payment of such funds to Pre-funded Vendors.

 

	 	D.	Payment
    Terms:

 

	 	i.	Medpace
    shall not invoice any amounts in excess of those specified in the Project Budget approved in writing by Sponsor. Unless otherwise
    agreed to in the applicable Task Order, Sponsor shall mail or wire undisputed payments to Medpace within 45 days after receipt
    of a written invoice and required supporting documentation as applicable. If any portion of an invoice is disputed, then Sponsor
    shall pay the undisputed amounts as set forth in the preceding sentence and the Parties shall use good faith efforts to reconcile
    the disputed amount. If Sponsor wishes to dispute an invoice, Sponsor will notify Medpace of any disputed amounts within thirty
    (30) days of the date of receipt of any invoice (“Sponsor Dispute Notice”). The Parties’ project teams will
    use good faith efforts to resolve such dispute within twenty (20) days of the date of the Sponsor Dispute Notice. The Parties
    agree that the result of these discussions will be binding on both Parties, and if the Parties fail to reach a resolution
    after said discussions, either Party may move forward with its rights under law and this Agreement. An annual interest rate
    of 8% (or the maximum allowed by law) will be applied to outstanding undisputed invoices greater than 30 days beyond the due
    date, with such interest rate being assessed from the due date of the undisputed invoice. The Parties will work in good faith
    to establish a Payment Schedule in the applicable Task Order(s).

 

    	 	 	6 | Page

    	 

    

 

	 	ii.	Medpace
    shall limit the costs and expenses associated with this Agreement and shall pass along to Sponsor all available discounts,
    or rebates and allowances directly related to the Services. All payments shall be made in United States Dollars ($) (the “Contracted
    Currency”) unless otherwise agreed to in writing by the Parties and set forth in applicable Task Order.
	 	 	 
	 	iii.	The
    Project Budget is exclusive of all taxes, including without limitation federal, state and local income taxes; franchise taxes;
    federal, state and local sales and use taxes (except and not including sales or use taxes imposed on account of a transaction
    made under this Agreement); gross receipts taxes; property taxes; value-added taxes; and custom duty taxes. Medpace will use
    reasonable best efforts to include an estimate of such taxes in the Project Budget. However, all such expenses may not be
    known at the time of Task Order execution. Sponsor will be responsible for all such taxes due in connection with this Agreement.
    All such sales and/or use taxes shall be shown on supporting documentation and provided to Sponsor.
	 	 	 
	 	iv.	Medpace
    understands and agrees that for purposes of complying with Sponsor’s reporting obligations under the Patient Protection
    and Affordable Care Act of 2010 (together with any regulations and official guidelines promulgated thereunder) and any applicable
    U.S. state reporting requirements, Sponsor may collect, aggregate, and report any and all payments made pursuant to this Agreement.

 

	5.	WARRANTIES
    AND REPRESENTATIONS:

 

	 	A.	Acknowledgements:

 

	 	i.	Medpace
    acknowledges that the Services to be provided hereunder are for the benefit of, and are subject to the direction of Sponsor.
    Medpace acknowledges that Sponsor is the beneficiary under the terms of this Agreement and each Task Order, and that Sponsor
    is entitled to enforce the provisions thereof.
	 	 	 
	 	ii.	In
    carrying out its responsibilities under this Agreement and each Task Order, neither Party nor any of its respective representatives
    or Affiliates will pay, offer or promise to pay, or authorize the payment of, any money, or give or promise to give, or authorize
    the giving of, any services or anything else of value, either directly or through a third party, to any official or employee
    of any governmental authority or instrumentality, or of a public international organization, or of any agency or subdivision
    thereof corruptly for the purpose of improperly (i) influencing any act or decision of that person in his official capacity,
    including a decision to fail to perform his functions with such governmental agency or instrumentality or such public international
    organization or such political party, (ii) inducing such person to use his influence with such governmental agency or instrumentality
    or such public international organization or such political party to affect or influence any act or decision thereof or (iii)
    securing any improper advantage; provided however, the foregoing representation shall not apply to any facilitating or expediting
    payment to a foreign official, political party, or party official the purpose of which is to expedite or to secure the performance
    of a routine governmental action by a foreign official, political party, or party official. Medpace agrees to report immediately
    to Sponsor any direct or indirect requests for payments to, or for the benefit of, a government official, including facilitation
    payments, as well as any payments that are made to Medpace in connection with the Services contemplated by this Agreement.

 

    	 	 	7 | Page

    	 

    

 

	 	B.	Representations
    and Warranties of Medpace:

 

	 	i.	Medpace
    represents and warrants that it is duly organized, validly existing and in good standing in its place of organization, and
    is in good standing and duly qualified to do business in all locations where qualification is required in order for Medpace
    to provide the Services.
	 	 	 
	 	ii.	Medpace
    warrants that the execution, delivery and performance of this Agreement and each Task Order has been validly authorized by
    all corporate action and this Agreement and each Task Order represents the valid binding agreement of Medpace enforceable
    in accordance with its terms. The execution, delivery and performance of this Agreement and each Task Order will not violate
    any organizational document governing Medpace, any material agreement to which Medpace is a party, or any law or court or
    governmental order to which Medpace is bound. Medpace further warrants that it shall render the Services requested by Sponsor
    in accordance with high professional standards, consistent with Good Clinical Practices and with the standard of care customary
    in the contract research organization industry.
	 	 	 
	 	iii.	Medpace
    warrants that the personnel assigned to perform Services rendered under this Agreement shall be qualified and professionally
    capable of performing the Services, shall be adequate to effectively perform the Services on the agreed upon schedule and
    shall devote such time as is necessary to perform the Services on such agreed upon schedule.
	 	 	 
	 	iv.	Medpace
    further warrants that it shall perform the Services in compliance with the terms of this Agreement and applicable Task Order,
    the protocol for the applicable Study and all Applicable Laws including, without limitation, the Federal Food, Drug and Cosmetic
    Act and the regulations promulgated pursuant thereto, and all future amendments during the term. Medpace further warrants
    that it shall make available to Sponsor, or to the responsible regulatory authority, relevant records, programs and data as
    may reasonably be requested by Sponsor or which is the subject of a Task Order. In accordance with Article 16, Sponsor shall
    have the right to monitor the operations of Medpace hereunder, and Sponsor representatives shall have the right to visit any
    of the facilities where Medpace is performing any of the Services and during such visits to inspect the work being done and
    materials used, to observe the procedures being followed, to examine the books, records and other data relevant to the Services.
    If any regulatory agency requests to inspect any books, records, data of Medpace relating to the Services, Medpace shall immediately
    notify Sponsor within one (1) business day. Medpace shall notify Sponsor promptly of any governmental or regulatory correspondence,
    inquiry, or other communication directed to Medpace or of which Medpace becomes aware that concerns: (A) a Study, including
    without limitation inspections of Study Sites; (B) any Services; or (C) Sponsor (collectively, the “Regulatory Communications”).
    Medpace shall, unless prohibited by the applicable governmental or regulatory agency or confidentiality obligations, promptly
    forward to Sponsor copies of all Regulatory Communications and all correspondence or other documentation from any governmental
    or regulatory agency or competent authority related to any Regulatory Communication. In that event and to the extent permitted
    by Applicable Law, Medpace will consult with and allow Sponsor to review and comment on any responses or other communications
    made by Medpace to the authority relating to the inspection, Study, Services, and/or Sponsor, and Medpace shall consider and
    use good faith efforts to incorporate Sponsor’s reasonable input; however, Sponsor acknowledges that it is Medpace’s
    obligation to respond to an inspection notice directed to Medpace. Medpace shall otherwise cooperate with Sponsor in good
    faith in responding to any Regulatory Communications. To the extent permitted by Applicable Law, and at Sponsor’s own
    expense, Sponsor shall be given the opportunity to have a representative present during any inspection, audit, meeting, videoconference,
    telephone call, or similar discussion with any governmental or regulatory authority related to a Study, or to Services performed
    under this Agreement, or to Sponsor.

 

    	 	 	8 | Page

    	 

    

 

	 	v.	Medpace
    represents and warrants that there is no litigation, regulatory investigation or proceeding, administrative hearing or any
    other similar proceeding pending or to the best of its knowledge threatened against Medpace which could materially adversely
    affect Medpace’s ability to perform the Services.
	 	 	 
	 	vi.	Medpace
    has developed a business interruption and disaster recovery program and is executing such program to assess and reduce the
    extent to which Medpace’s hardware, software and embedded systems may be susceptible to errors or failures in various
    crisis (or force majeure) situations. Medpace shall employ all reasonable and appropriate measures and processes to insure
    that all data collected and stored by it pursuant to this Agreement will be safeguarded against loss, damage and destruction
    arising from any cause including, but not limited to, theft, fire, flood, earthquake, lightening, and electrical disruption.
    Such measures and processes shall include, but not be limited to, (A) storage of hard-copy documents and computer storage
    disks in locked, fireproof containers, and (B) back-up and recovery systems (which are periodically tested) for computer-based
    systems. Sponsor shall have the right, but not the obligation, upon reasonable advance written notice and during normal business
    hours, to periodically inspect Medpace’s premises to determine whether the foregoing measures and processes are in effect
    and being implemented. In the event that any data, reports or materials that are delivered by Medpace to Sponsor are inaccurate
    as a result of such errors or failures then Medpace will fix, or if necessary, re-perform the deliverables with no increase
    to direct fees to Sponsor, within mutually agreeable time frames.

 

    	 	 	9 | Page

    	 

    

 

	 	vii.	if
    Medpace uses electronic systems for creating, modifying, maintaining, archiving, retrieving or transmitting any records, including
    test results that are required by, or subject to inspection by an applicable regulatory authority (including the FDA), then
    Medpace represents and warrants that Medpace’s systems for electronic records are in compliance with 21 CFR Part 11.
    Medpace further represents and warrants that, in order to comply with Part 11, it will not use any electronic signatures on
    any documents required by, submitted to, or supporting a submission to the FDA unless Medpace, as applicable, has certified
    to the FDA that it intends such electronic signatures to be the legally binding equivalent of a hand-written signature.

 

	 	C.	Representations
    and Warranties of Sponsor

 

	 	i.	Sponsor
    represents and warrants that it is duly organized, validly existing and in good standing in its place of organization, and
    is in good standing and duly qualified to do business in all locations where qualification is required for Sponsor to engage
    in its business.
	 	 	 
	 	ii.	Sponsor
    warrants that the execution, delivery and performance of this Agreement and each Task Order has been validly authorized by
    all corporate action and this Agreement and each Task Order represents the valid binding agreement of Sponsor enforceable
    in accordance with its terms. The execution, delivery and performance of this Agreement and each Task Order will not violate
    any organizational document governing Sponsor, any material agreement to which Sponsor is a party, or any law or court or
    governmental order to which Sponsor is bound.
	 	 	 
	 	iii.	Sponsor
    further warrants that it shall comply with all Applicable laws in performing its obligations hereunder.
	 	 	 
	 	iv.	Sponsor
    represents and warrants that there is no litigation, regulatory investigation or proceeding, administrative hearing or any
    other similar proceeding pending or to the best of its knowledge threatened against Sponsor which could materially adversely
    affect Sponsor’s ability to perform under this Agreement or any Task Order.
	 	 	 
	 	v.	SPONSOR
    MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING AND WITHOUT LIMITATION ANY OF THE IMPLIED WARRANTIES OF MERCHANTABILITY,
    FITNESS FOR A PARTICULAR PURPOSE REGARDING THE STUDY DRUG OR ANY OTHER SUBJECT MATTER OF THIS AGREEMENT AND WITHOUT ANY REPRESENTATION
    OR WARRANTY THAT THE USE OF THE STUDY DRUG WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHT OF A THIRD PARTY.
    SPONSOR MAKES NO REPRESENTATION OF ANY KIND, EXPRESS OR IMPLIED, REGARDING THE SAFETY OR EFFICACY OF THE STUDY DRUG OR ANY
    OTHER SUBJECT MATTER OF THIS AGREEMENT.
	 	 	 
	 	vi.	Sponsor
    represents and warrants that, to its knowledge, it has and will have for the duration of any Task Order(s) the financial resources
    that are necessary to meet its financial obligations under this Agreement and each Task Order.

 

    	 	 	10 | Page

    	 

    

 

	6.	TERMINATION

 

	 	A.	The
    term of this Agreement shall be for four (4) years from the Effective Date unless earlier terminated as permitted herein.
    Any Task Order, the duration of which extends beyond the expiration or termination of this Agreement, will continue to be
    performed for the term of such Task Order, and will continue to be governed by the terms of this Agreement, which terms shall
    remain in effect beyond the expiration or termination of this Agreement solely with respect to such Task Order.
	 	 	 
	 	B.	Sponsor
    may terminate this Agreement or any Task Order without cause immediately upon giving Medpace notice of such termination.
	 	 	 
	 	C.	Medpace
    may terminate a Task Order if Sponsor has materially defaulted on its obligations under this Agreement or any Task Order and
    has not cured such material default (i) within 30 days after Sponsor’s receipt of a written notice of default from Medpace
    if the material default is the failure to pay Medpace any undisputed amount due hereunder or (ii) within 60 days after receipt
    of written notice in the event of any other material default or where such material default is not susceptible to cure within
    60 days or the defaulting Party fails to commence to cure such material default within such 60 day period.
	 	 	 
	 	D.	As
    soon as practicable after receipt of such termination notice, the Parties shall cooperate in good faith to agree on a plan
    to expeditiously conclude activities and outstanding obligations of each Party with respect to this Agreement and any applicable
    Task Order, including transfer of all case report forms, Study files, and other data and information in Medpace’s possession
    or control to Sponsor. Medpace shall not, without Sponsor’s prior approval, perform any additional Services, incur expenses,
    or enter into any other obligations related to the Agreement or the terminated Task Order, as applicable, except to the extent
    requested by Sponsor or required by and with due regard for Study subject safety and welfare. In the event that Medpace terminates
    a Task Order for Sponsor’s breach under Section 6(C), Medpace shall have the right to cease performance of Services
    and shall have no obligation to perform additional Services, to transfer Deliverable or Work Product(s), or to provide access
    to Medpace systems, unless otherwise required by any Applicable Law or in the interest of Study subject safety. Sponsor shall
    not be liable to Medpace for any loss of business opportunity or lost profit.
	 	 	 
	 	E.	In
    the event of any termination of a Task Order before completion, Sponsor agrees to pay Medpace for all Services rendered pursuant
    to the unfinished Task Order prior to such termination and any reasonable and necessary non-cancelable expenses incurred in
    connection with Medpace’s performance of Services thereunder and pre-approved in writing by Sponsor as well as any close-out
    activities mutually agreed upon in writing by the Parties. As soon as reasonably practicable following receipt of a termination
    notice, Medpace shall submit an itemized accounting of Services performed, expenses incurred pursuant to performance of the
    Services, non-cancelable expenses incurred by Medpace relating to any unfinished Task Order, and payments received in order
    to determine a balance to be paid by either Party to the other. Such balance shall be paid within 30 days of receipt of such
    an itemized accounting by Sponsor.
	 	 	 
	 	F.	The
    following Articles of this Agreement shall survive the expiration or earlier termination of this Agreement: 6 – 11,
    14 – 17, and 19-20.
	 	 	 
	 	G.	In
    the case of material breach by Sponsor due to a failure to pay amounts due to Medpace, Medpace shall have no obligation to
    transfer Deliverables or Work Product(s), until such breach is cured, unless otherwise required by applicable law.

 

    	 	 	11 | Page

    	 

    

 

	7.	COMMUNICATIONS

 

	 	A.	Any
    notice required or permitted under this Agreement shall be in writing and shall be deemed given if delivered personally, mailed
    by prepaid, first class, certified mail, return receipt requested, or sent by express courier service, to the Party to be
    notified at the addresses set forth below (or such other address as shall be designated by written notice); provided that
    all notices shall be effective upon receipt thereof:

 

If
to Medpace:

 

Medpace,
Inc.

5375
Medpace Way

Cincinnati,
OH 45227

Attn:
General Counsel

Telephone:
(513) 579-9911

 

If
to Sponsor:

 

Ritter
Pharmaceuticals, Inc.

1880
Century Park East #1000

Los
Angeles, CA 90067

Attn:
Andrew Ritter, President

Email
for invoices: ap@ritterpharma.com

Email
for all other notices: andrew@ritterpharma.com

Telephone:
(310) 203-1000

 

	8.	CONFIDENTIALITY

 

	 	A.	Either
    Party or its Affiliates (the “Disclosing Party”) may provide its confidential information to the other Party or
    its Affiliates (the “Receiving Party”) during the course of this Agreement.
	 	 	 
	 	B.	All
    information provided by Sponsor or on Sponsor’s behalf or data collected by Medpace for Sponsor during the course of
    performance of the Services is deemed to be the confidential information of Sponsor (“Sponsor Confidential Information”).
    “Sponsor Confidential Information” includes without limitation: (i) Sponsor’s or its Affiliate’s business
    records, oral or electronic communications, financial information, business practices, trade secrets, know-how, intellectual
    property, materials, inventions, formulas, compounds, devices, specifications, designs, plans, methods, software, data, technical
    information, concepts, procedures, processes, business plans, current and past distribution and production arrangements (oral
    or written), facilities, employees, marketing and sales strategies, business opportunities and strategic plans; (ii) information
    related to or arising from any proprietary compounds of Sponsor or Sponsor’s Affiliates that is developed by Medpace
    in connection with the performance of the Services hereunder; (iii) Sponsor Arising IP; (iv) information that is generated
    or developed by or received from Study Sites by Medpace in connection the performance of Medpace’s Services under the
    applicable Task Order; and (v) the terms of this Agreement.

 

    	 	 	12 | Page

    	 

    

 

	 	C.	Medpace
    may provide confidential information to Sponsor during the course of this Agreement (“Medpace Confidential Information”).
    Medpace Confidential Information shall include but is not limited to standard operating procedures, pricing, and financial
    information provided by Medpace or its Affiliates to Sponsor during the course of performance of the Services, and any non-public
    information pertaining to Medpace’s business practices or other proprietary information. “Confidential Information”
    refers to Sponsor Confidential Information and Medpace Confidential Information. Each Receiving Party shall not disclose the
    Disclosing Party’s Confidential Information to any third party, or use the Disclosing Party’s Confidential Information
    for any purpose other than for those set forth under this Agreement or a Task Order, without the prior written consent of
    the Disclosing Party.

 

	 	i.	Each
    Receiving Party shall ensure that its and its Affiliate’s directors, officers, employees, Subcontractors, and approved
    independent contractors (collectively, “Representatives”) shall comply with the provisions of Article 8 of this
    Agreement. Receiving Party shall disclose the Disclosing Party’s Confidential Information only to those of its Representatives
    who need to know the Disclosing Party’s Confidential Information for performance of their obligations under this Agreement
    and are bound by written nondisclosure obligations at least as stringent as those set forth herein. Receiving Party shall
    be liable for any breach of the terms of this Agreement by its Representatives.
	 	 	 
	 	ii.	Receiving
    Party shall exercise due care, but no less than a reasonable degree of care, to prevent the unauthorized disclosure and use
    of the Disclosing Party’s Confidential Information.

 

	 	D.	The
    foregoing obligations of confidentiality and non-use shall not apply to the extent that any information is:

 

	 	i.	Information
    which was known by a Receiving Party before disclosure by the Disclosing Party in connection with the Services or this Agreement
    (including any Task Order) or which is independently discovered by the Receiving Party, after the date hereof, without the
    aid, application or use of the Confidential Information of the Disclosing Party, as evidenced by competent written records
    maintained in the ordinary course of business;
	 	 	 
	 	ii.	Information
    which is in the public domain on the date hereof or subsequently becomes publicly available through no fault or action of
    a Receiving Party or its Representatives; or
	 	 	 
	 	iii.	Information,
    which is disclosed to the Receiving Party by a third party not under any obligation prohibiting the disclosure of such Confidential
    Information.

 

    	 	 	13 | Page

    	 

    

 

	 	E.	If
    the Receiving Party is requested to disclose any Confidential Information of the Disclosing Party or the substance of this
    Agreement in connection with a legal or administrative proceeding or otherwise to comply with a requirement under the law,
    the Receiving Party will give the Disclosing Party (to the extent permitted by Applicable Law) prompt notice of such request
    so that the Disclosing Party may seek an appropriate protective order or other remedy, or waive compliance with the relevant
    provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party, at the
    Disclosing Party’s expense, will reasonably cooperate with and assist the Disclosing Party in such efforts. Failure
    of the Disclosing Party to intervene shall not relieve the obligations to maintain confidentiality except in so far as the
    Receiving Party must comply with the terms of such process compelling disclosure.
	 	 	 
	 	F.	The
    Parties acknowledge that any breach or threatened breach of this Article may result in irreparable harm to the non-breaching
    Party for which monetary damages would be an inadequate remedy. Therefore, the Parties agree that, in the event of such breach
    or threatened breach of this Section, in addition to all other remedies available under law, the non-breaching Party shall
    be entitled, as a matter of right, to equitable relief, including an injunction, without being required to post a bond or
    other security. Such equitable relief shall be in addition to the non-breaching Party’s rights and remedies otherwise
    available at law.
	 	 	 
	 	G.	Medpace
    acknowledges that, in connection with its performance of the Services, it may receive or gain access to “Nonpublic Personal
    Information” or “NPI.” As used herein, NPI shall mean information that Medpace creates or receives from
    or on behalf of Sponsor that is not publicly available and that, in itself or as part of a unique combination of data or information,
    identifies or could be used to identify an individual, whether by unique descriptors and/or identifiers, including but not
    limited to social security numbers, health plan/insurance policy numbers, financial account (including credit card/debit card)
    numbers, driver’s license numbers, health or biometric related information, and/or any other unique identifying numbers,
    characteristics, or codes. During the term of this Agreement, Medpace shall use and disclose NPI only as necessary to perform
    the Services and the specific obligations for which such information was disclosed to Medpace pursuant to the Agreement. Medpace
    shall treat all NPI as confidential in accordance with all Applicable Laws, including HIPAA and HITECH.
	 	 	 
	 	H.	The
    non-disclosure obligations under this Article 8 shall survive any expiration or termination of this Agreement for seven (7)
    years. Upon expiration or termination of this Agreement or earlier at the Disclosing Party’s written request, the Receiving
    Party will, at the option and expense of the Disclosing Party, return or destroy the Disclosing Party’s Confidential
    Information, except that in any event the Receiving Party may retain a single copy of the Disclosing Party’s Confidential
    Information solely for archival purposes.

 

    	 	 	14 | Page

    	 

    

 

	9.	RIGHTS
    IN PROPERTY

 

	 	A.	All
    materials, documents, data, software and information of every kind and description supplied to Medpace by Sponsor or on behalf
    of Sponsor, or prepared, developed, or generated by Medpace pursuant to this Agreement, (except for the Medpace Property)
    are and shall be the sole and exclusive property of Sponsor (“Sponsor Property”). Further, all inventions, processes,
    know-how, trade secrets, improvements, copyrights, trademarks and/or patents, other intellectual property, data and information
    relating to the Study drug or otherwise arising from the Study, Sponsor Confidential Information, Study protocol, or Medpace’s
    performance of Services under this Agreement that are conceived, reduced to practice and/or generated hereunder during the
    term of this Agreement or subsequent to the termination or expiration of this Agreement shall be and remain the exclusive
    property of Sponsor (collectively with Sponsor Property, “Sponsor Arising IP”). Sponsor shall have the right to
    make whatever use they deem desirable of any such Sponsor Arising IP. Medpace shall not, without the prior written consent
    of Sponsor, publish, disseminate, or otherwise disclose to any third party any such Sponsor Arising IP (except such disclosure
    as may be required by law), or use any such property for any purpose other than the performance or enforcement of this Agreement.
    Sponsor Arising IP shall include, without limitation, any Study reports, data summaries, data analyses, patient narratives,
    annotated package inserts, Study publications, or other written, printed, or graphic works or documents or other work product
    created by Medpace under a Task Order. Medpace hereby assigns, and shall require, its Representatives to assign, its rights
    in all such Sponsor Arising IP to Sponsor consistent with the obligations set forth in Article 10 below.
	 	 	 
	 	B.	Sponsor
    acknowledges that all computer programs, software, applications, databases, proposals and other documentation that (i) are
    generally used by Medpace in the conduct of its business, (ii) do not incorporate, arise from or rely on Sponsor Confidential
    Information or the Study drug, and (ii) are not directly derived from or developed solely for Sponsor, are the exclusive and
    confidential property of Medpace or the third parties from whom Medpace has secured the right of use (“Medpace Property”).
    Sponsor agrees that any improvement, alteration or enhancement to Medpace Property which are developed or implemented during
    the course of any Services performed hereunder, without incorporating, arising from or reliance on any Sponsor data, information,
    materials, Study drug or Confidential Information (or derivatives thereof), shall be the property of Medpace.
	 	 	 
	 	C.	Medpace
    covenants that it shall not embed any Medpace Property or improvements, alterations or enhancements in any Sponsor Arising
    IP. To the extent that any Medpace Property or improvements, alterations or enhancements thereto is incorporated into any
    Sponsor Arising IP hereunder, Medpace hereby grants Sponsor and its Affiliates a non-exclusive, worldwide, irrevocable, sublicenseable,
    transferable, royalty-free right and license, for it to use the Medpace Property and improvements, alterations and enhancements,
    as applicable, solely in connection with its use of the Sponsor Arising IP which may be used for any and all purposes. Medpace
    represents and warrants that to the best of its knowledge Medpace’s licensing of such intellectual property for Sponsor’s
    use solely in connection with the Sponsor Arising IP is properly authorized and will not constitute an infringement or other
    violation of any rights of a third party.

 

    	 	 	15 | Page

    	 

    

 

 

 

	10.	PATENT
    RIGHTS

 

	 	A.	Medpace
    shall disclose promptly to Sponsor any and all inventions, discoveries and improvements conceived or made by Medpace while
    providing Services to Sponsor pursuant to the Agreement and constituting a modification or extension of use relating to Sponsor’s
    proprietary rights, and hereby assigns all its interest therein to Sponsor or its nominee; whenever requested to do so by
    Sponsor, Medpace shall, and shall ensure that its Representatives will, execute any and all applications, assignments, or
    other instruments and give testimony which Sponsor shall deem necessary to apply for and obtain a patent in the United States
    of America and/or other applicable jurisdiction or of any foreign country or to protect otherwise Sponsor’s interests
    and shall compensate Medpace for the time devoted to said activities and reimburse it for expenses incurred.

 

	11.	PUBLICITY

 

	 	A.	Medpace
    shall not make any public announcements, oral presentations or publications concerning this Agreement or the subject matter
    hereof without the prior written consent of Sponsor.

 

	 	B.	Medpace
    will not use the Sponsor’s name, logo or trademark in any communication, release, notice or other publication without
    the express prior written consent of the Sponsor; provided, however, Medpace may disclose Sponsor’s name to the extent
    required by Applicable Law. Sponsor will not use Medpace’s name, logo or trademark for any marketing purpose without
    Medpace’s prior written consent; provided, however, Sponsor may disclose Medpace’s name for all other purposes,
    including to the extent required by Applicable Law or for regulatory purposes.

 

	12.	SECURITY
    AND DISPOSITION OF STUDY FILES

 

	 	A.	Medpace
    shall use commercially reasonable efforts, including, but not limited to, periodic backup of computer files, to prevent the
    loss or alteration of Sponsor’s Study data, Confidential Information, documentation, and correspondence. Medpace shall
    in all respects comply with any Food and Drug Administration (“FDA”) regulations concerning the maintenance, creation
    and storage of records, including electronic records.

 

	 	B.	Except
    as otherwise provided in this Agreement, at appropriate time points or at completion of Services under a Task Order, Medpace
    shall transfer Study materials, documents and correspondence to Sponsor. Medpace shall have the right to retain one copy of
    any Study materials, documentation, and correspondence necessary solely to meet regulatory or Medpace’s own internal
    audit requirements, so long as it continues to maintain the confidentiality requirements of Article 8.

 

    	 	 	16 | Page

    	 

    

 

	13.	SPONSOR
    OBLIGATIONS

 

	 	A.	Sponsor
    acknowledges that performance of the Services by Medpace will require the co-operative involvement of both Parties, and Sponsor
    hereby agrees to provide such assistance as may be reasonably necessary to enable Medpace to perform the Services.

 

	14.	INDEMNIFICATION

 

	 	A.	Sponsor
    shall indemnify, defend and hold harmless Medpace and its Affiliates and their respective officers, directors, employees and
    agents (“Medpace Indemnitees”) from and against any and all damages, losses, liabilities, costs or expenses, including
    reasonable attorneys’ fees (collectively “Damages”), resulting or arising from any claims, demands, assessments,
    actions, suits, investigations or proceedings brought by a third party (collectively “Claims”), arising from Services
    performed by Medpace pursuant to this Agreement or under any Task Order (including but not limited to any Damages arising
    from or in connection with any Study, test, product or potential product to which this Agreement relates, or actions necessitated
    by the protocol), except to the extent such Claims or Damages are determined to have resulted from Medpace or its Representative’s
    negligence, willful misconduct, or breach of any Applicable Law or breach of this Agreement or any Task Order.

 

	 	B.	Medpace
    agrees to indemnify, defend and hold harmless Sponsor and its Affiliates and their respective officers, directors, employees
    and agents (“Sponsor Indemnitees”) from and against any and all Damages resulting or arising from Claims arising
    from Medpace or Medpace’s Representative’s negligence or willful misconduct or a breach of any Applicable Law
    or a breach of this Agreement or any Task Order.

 

	 	C.	Any
    Party providing indemnification under this Agreement shall have the right to control the defense and settlement of any Claims
    or Damages; provided that neither Party will settle a Claim on behalf of the other Party without the prior written approval
    of that Party. The indemnified Party shall have the right to obtain separate legal counsel at its own expense if it so chooses.
    No such Claim shall be settled without the prior written consent of the indemnifying Party, which consent shall not be unreasonably
    withhold. The indemnified Party shall reasonably cooperate in the defense of any Claims or Damages and provide prompt written
    notice to the indemnifying Party of any Claims or Damages for which indemnification is sought, provided that a failure to
    provide such notice shall not relieve the indemnifying Party of its obligation, except to the extent it is materially prejudiced
    by the failure to provide notice.

 

	 	D.	During
    the term of this Agreement and for the duration of any applicable Task Order, Medpace shall maintain liability insurance with
    policy limits sufficient to meet its indemnification obligations under this Agreement. During the term of this Agreement,
    Sponsor will, at its own expense, procure and maintain insurance at appropriate levels. A Certificate of Insurance will be
    provided to the other Party upon request.

 

    	 	 	17 | Page

    	 

    

 

	15.	LIMITATION
    OF LIABILITY

 

	 	A.	Except
    in the event of a liable party’s indemnification obligations or breach of confidentiality obligations hereunder, In
    no event shall Sponsor or Medpace be liable for any lost profits or indirect, incidental, special or consequential damages
    arising out of the provision of Services hereunder, even if the party seeking recovery of such damages has been advised of
    the possibility of such damages.

 

	16.	INSPECTIONS AND AUDITS

 

	 	A.	With
    respect to each Study, Medpace will retain all Study records and documents for the greater of the duration of the Study or
    as required by Applicable Laws. Medpace shall notify Sponsor six (6) months prior to the expiration of the above referenced
    document retention period to determine whether Sponsor plans to take delivery of the Study records and documents or require
    post Study record and document retention services at Sponsor’s cost as mutually agreed to by the Parties. During the
    duration of the Study, Sponsor or its designee shall have the right, upon at least ten business (10) days’ prior written
    notice to Medpace (except for for-cause audits), to examine the standard operating procedures, facilities, books, records,
    papers, files and documentation, including computer files, data bases and records, at Medpace’s facilities and the facilities
    of clinical investigators contracted by Medpace to determine the adequacy of such records, to ensure the Services are being
    performed in accordance with the approved Task Orders and applicable regulations and/or to examine the financial records of
    Medpace as may be reasonably necessary to verify out-of-pocket expenses incurred during the performance of the Services. Such
    inspections and audits shall be conducted during normal business hours.

 

	 	B.	Medpace
    shall provide reasonable assistance, including making available members of its staff and providing access to all requested
    records, to facilitate such inspections and audits.

 

	 	C.	Medpace
    shall take all reasonable steps required by Sponsor to cure any Medpace deficiencies found in any audit, inspection or investigation.

 

	17.	DEBARMENT

 

	 	A.	Medpace
    hereby represents, warrants, and certifies that neither it nor any of its Representatives has been or will be at any relevant
    time hereunder (i) debarred under Section 306 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §335a(a) or (b),
    or similar local law nor (ii) threatened to be debarred or voluntarily excluded or indicted for a crime or otherwise engaged
    in conduct for which a person can be debarred under § 335a (collectively, (i) and (ii) above, (“Debarred”),
    or subject to any governmental sanction that would prevent the rendering of services hereunder in any jurisdiction in which
    the Study is to be conducted, nor (iii) excluded from participation in any federally-funded health-care program (“Excluded”).
    In the event that any such party becomes Debarred or Excluded, Medpace shall notify Sponsor in writing immediately and Sponsor
    shall have the right to immediately terminate this Agreement if the above representation is or becomes untrue.

 

    	 	 	18 | Page

    	 

    

 

	 	B.	Medpace
    hereby represents, warrants, and certifies that it has not and shall not use in any capacity the services of any individual,
    corporation, partnership, or association which has been Debarred or Excluded. In the event Medpace becomes aware of or receives
    notice of the Debarment or Exclusion of any individual, corporation, partnership, or association providing services to Medpace,
    which relate to the Services being provided under this Agreement, Medpace shall notify Sponsor in writing immediately and
    Sponsor shall have the right to immediately terminate this Agreement if the above representation is or becomes untrue.

 

	18.	NON
    SOLICITATION. 

 

Neither
Party and its Affiliates shall during the term of this Agreement and for a period of twelve months following its termination,
either directly or indirectly, hire any employee of the other Party with whom its comes into contact as a result of providing
the Services, or recruit, solicit, or entice any such person to become employed by it or any Affiliate and shall not approach
any such employee for such purpose or encourage, authorize or approve the taking of such action by any other person. The Parties
agree that any breach of this provision would cause irreparable harm and that in addition to any and all other available remedies
injunctive relief, without the necessity of a bond or other security, shall be appropriate and available. Notwithstanding the
foregoing, the Parties acknowledge and agree that this Section 18 will not prohibit solicitations by either Party through use
of general advertising or other publications of general circulation.

 

	19.	ENTIRE
    AGREEMENT

 

This
Agreement contains the full understanding of the Parties with respect to the subject matter hereof and supersedes all existing
agreements and all other oral, written or other communications between the Parties concerning the subject matter hereof. This
Agreement shall not be amended, modified or supplemented in any way except in writing and signed by a duly authorized representative
of Sponsor and Medpace. All Appendices hereto, including any Task Orders, shall be deemed to be incorporated herein and made a
part hereof.

 

	20.	GOVERNING
    LAW

 

	 	A.	This
    Agreement and the performance hereof shall be governed, interpreted and construed in all respects by the internal laws of
    the State of New York, without respect to its conflict of law principles. All disputes and claims arising under this Agreement
    or any Task Order shall be resolved exclusively in a court of applicable jurisdiction located in New York and each Party consents
    to the venue of any such action.

 

	21.	NO
    WAIVER

 

	 	A.	No
    waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances
    shall be deemed to be or construed as a further or continuing waiver of any such term, provisions, or conditions, or of any
    other term, provision, or condition of this Agreement. No waiver of any right set forth herein shall be deemed effective unless
    in writing and signed by the Party against whom enforcement of the waiver is sought.

 

    	 	 	19 | Page

    	 

    

 

	22.	INDEPENDENT
    CONTRACTOR

 

	 	A.	In
    fulfilling its obligations pursuant to this Agreement, each Party shall be acting as an independent contractor and the Services
    do not create an employee/employer relationship between the Parties. Neither Party is granted any right or authority to assume
    or to create any obligation or responsibility, expressed or implied, on behalf of or in the name of the other Party.

 

	23.	FORCE
    MAJEURE

 

	 	A.	Neither
    Party shall be liable or deemed to be in default for any delay due to causes beyond the reasonable control of the Party and
    not the result of such Party’s negligence or willful misconduct, such as: war, acts or threats of terrorism, civil disorders,
    acts of God, or government action; provided, that the affected Party promptly notifies the other of the cause and its effects
    on the Services to be performed hereunder and uses all reasonable endeavors to eliminate or cure or overcome any such causes
    and to resume performance of its covenants with all possible speed. Financial difficulty shall never be deemed a force majeure
    event. Notwithstanding anything to the contrary herein, in the event the force majeure event continues for more than sixty
    (60) days, the non-affected Party shall have the right to terminate this Agreement immediately upon written notice to the
    affected Party. Notwithstanding the foregoing, in no event shall the occurrence of a force majeure event excuse Medpace from
    its obligations if such event was reasonably foreseeable and Medpace did not take all reasonable measures to protect against
    its occurrence.

 

	24.	SEVERABILITY

 

	 	A.	In
    the event any provision of this Agreement shall be determined to be void or unenforceable, the remaining provisions shall
    remain in full force and effect.

 

	25.	ASSIGNMENT

 

	 	A.	Except
    as set forth herein, Medpace shall not assign this Agreement or any Task Order except with the prior written consent of Sponsor.
    No assignment by either Party, however, will relieve either Party of the performance of any accrued obligation that such Party
    may then have under this Agreement. Subject to the restrictions set forth in this Section, this Agreement shall be binding
    upon and shall inure to the benefit of the Parties’ permitted successors and assigns. Any attempted assignment in violation
    of this section shall be deemed null and void.

 

	26.	No
    Third Party Beneficiaries

 

	 	A.	Nothing
    herein, express or implied, is intended to or shall confer upon any other person or entity any right, benefit or remedy of
    any nature whatsoever under or by reason of this Agreement.

 

    	 	 	20 | Page

    	 

    

 

 

	27.	SUBCONTRACTING

 

	 	A.	Medpace
    shall not subcontract any such Service or obligation through sub-contractors, consultants, agents or any third party (“Subcontractors”)
    without first obtaining Sponsor’s written consent. In the event Sponsor approves the use of one or more Subcontractors,
    then Medpace shall enter into a separate contract with such Subcontractors containing terms consistent with this Agreement.
    Medpace shall require that any such contract shall contain the specific, detailed services to be performed by any such Subcontractor.
    Medpace shall use commercially reasonable efforts to add Sponsor as a third-party beneficiary to such contracts to allow Sponsor
    to exercise and enforce similar rights as Medpace may have under its contract with any such Subcontractor, including without
    limitation the right to audit and inspect such Subcontractor’s financial affairs, facilities, processes and procedures
    to the extent that such matters relate to work for Sponsor. Medpace’s contract with its Subcontractors shall include
    an assignment to Medpace of rights to any Sponsor Arising IP arising from the performance by such Subcontractor of any obligations
    subcontracted thereto pursuant to this paragraph. Medpace understands and agrees that all such Sponsor Arising IP described
    in the immediately preceding sentence shall be assigned to Sponsor as contemplated hereunder and as necessary Medpace shall
    apprise each Subcontractor of such fact. Medpace represents and covenants that it shall use best efforts to ensure that any
    Subcontractor, has the capability to perform the Services to Sponsor’s standards under this Agreement and in compliance
    with Applicable Laws. Study Sites shall not be considered a sub-contractor, consultant or agent for purposes of this Article.
    In the event that Medpace contracts with a Subcontractor pursuant to this Section to discharge any obligation of Medpace under
    this Agreement or a Task Order, Medpace shall (i) remain primarily responsible to Sponsor for the performance of such Service
    or obligations; and (ii) accept liability arising from the acts and omissions of any such Subcontractor related to performance
    of the Services.

 

	28.	SUCCESSORS
    AND ASSIGNS

 

	 	A.	This
    Agreement shall be binding on and inure to the benefit of the Parties hereto and their respective successors, heirs, personal
    representatives, and permitted assigns.

 

	29.	CONFLICTS
    BETWEEN AGREEMENTS

 

	 	A.	In
    the event that there is any conflict between the provisions of this Agreement and any duly executed Task Order, this Agreement
    shall control, unless the Task Order or this Agreement clearly states that in the event of such conflict, the Task Order shall
    control.

 

	30.	COUNTERPARTS

 

	 	A.	This
    Agreement and any Task Order may be executed in two or more counterparts, each of which shall be deemed an original, but all
    of which shall constitute the same agreement. Signatures to this Agreement transmitted by facsimile, by electronic mail in
    “portable document format” (“.pdf”), or by any other electronic means which preserves the original
    graphic and pictorial appearance of the Agreement or any Task Order, shall have the same effect as physical delivery of the
    paper document bearing the original signature.

 

    	 	 	21 | Page

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

 

	MEDPACE, INC.	 
	 	 	 
	Signature:	/s/  John Wynne	 
	By:	John Wynne	 
	Title: 	Vice President Commercial Operations	 
	 	 	 
	RITTER PHARMACEUTICALS, INC.	 
	 	 	 
	Signature:	/s/  Andrew J. Ritter	 
	By: 	Andrew J. Ritter	 
	Title: 	President and Co-Founder	 

  

    	 	 	22 | Page

    	 

    

 

EXHIBIT
A

 

FORM
OF TASK ORDER

 

Medpace
Task Order Number: ______________

 

Medpace
Project Number: ______________

 

This
Task Order, dated _______________, is between Medpace Inc. (“Medpace”), and Ritter Pharmaceuticals, Inc.
(“Sponsor”).

 

RECITALS:

 

WHEREAS,
Medpace and Sponsor have entered into that certain Master Services Agreement dated __________________ (as may be amended from
time to time, the “Master Services Agreement”); and

 

WHEREAS,
pursuant to the Master Services Agreement, Medpace has agreed to perform certain Services in accordance with Task Orders from
time to time entered into by the Parties and Sponsor and Medpace now desire to enter into such a Task Order; and

 

WHEREAS,
Medpace and Sponsor desire that Medpace provide certain services with respect to ______ (the “Study”) for the Study
of the product ________ (“Study Drug”) as set out in the Protocol Number: ____________, which is incorporated herein
by reference;

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

 

	 	1.	Scope
    of Work. Medpace shall perform the Services described in the Scope of Work, attached hereto as Appendix 1, in accordance
    with the Project Schedule, attached hereto as Appendix 2, the Study protocol, the terms of the Agreement and any other documents
    attached to and specifically referenced in this Task Order (“Services”).

 

	 	2.	Compensation.
    For performance of these Services, Sponsor shall pay to Medpace an amount equal to the Project Budget set forth in Appendix
    3, which amount shall be payable pursuant to the Payment Schedule set forth in Appendix 4. In no event shall the total fees
    payable by Sponsor pursuant to this Task Order exceed the Project Budget without Sponsor’s prior written consent. The
    Project Budget is provided for cost analysis purposes. It is agreed that all direct fees are fixed prices unless the underlying
    assumptions (including, but not limited to, trial duration, Study timelines, number of sites/patients, services provided)
    change and all such changes shall be documented in a Contract Amendment. After staff are assigned, costs are incurred based
    upon allocation of staff capacity.

 

	 	3.	Transfer
    of Obligations. Sponsor Obligations transferred to Medpace by Sponsor (consistent with the regulations set forth in
    21 C.F.R. Section 312, Subpart D) are identified in Appendix 5.

 

	 	4.	MSA.
    The provisions of the Master Services Agreement are hereby expressly incorporated by reference into and made a part
    of this Task Order.

 

    	23

    	 

    

 

IN
WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above.

 

	MEDPACE,
    INC.	 
	 	 	 
	Signature:
    	TEMPLATE
    NOT FOR SIGNATURE	 
	 	 	 
	By:	 	 
	Title:
    	 	 
	 	 	 
	RITTER
    PHARMACEUTICALS, INC.	 
	 	 	 
	Signature:	TEMPLATE
NOT FOR SIGNATURE	 
	 	 	 
	By:	 	 
		(Print
Name)	 
	Title:
    		 

 

List
of Appendices:

 

Appendix
1: Scope of Work

Appendix
2: Project Schedule

Appendix
3: Project Budget

Appendix
4: Payment Schedule

Appendix
5: Transfer of Obligations

 

    	24Exhibit

LONG-TERM PERFORMANCE AWARD AGREEMENT
Payable in Cash 
(Under the Kaman Corporation
2013 Management Incentive Plan)
THIS LONG-TERM PERFORMANCE AWARD AGREEMENT (this “Agreement”), is made and entered into as of the ____ day of February, 2018, by and between KAMAN CORPORATION, a Connecticut corporation with its principal office in Bloomfield, Connecticut (the “Company”), and ________________________ (the “Participant”);
Recitals:
A.    The Participant has been designated a Covered Employee under the Kaman Corporation 2013 Management Incentive Plan (the “Plan”), and the Committee wishes to grant the Participant a Cash-Based Award under Section 11 of the Plan (such Cash-Based Award being sometimes hereinafter referred to as the “Long-Term Performance Award”).  
B.    All capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to them in the Plan, except as provided in Section 10.
NOW, THEREFORE, in consideration of the premises, and of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:
1.Long-Term Performance Award.

(a)Subject to the terms and conditions of this Agreement, the Participant is hereby awarded a Cash-Based Award under Section 11 of the Plan, which shall entitle the Participant to a payment in cash to the extent that the Company attains the specified Performance Goals established by the Committee on the terms and conditions set forth below. The Performance Goals and the Performance Cycle to which the Performance Goals relate are set forth in Exhibit A to this Agreement, which is hereby incorporated herein by reference.  The Long-Term Performance Award is subject to forfeiture as more particularly described in Section 2 of this Agreement.

(b)In order for the Participant to be eligible to receive the payment which the Participant may otherwise earn pursuant to the Long-Term Performance Award, the Participant must execute and deliver a copy of this Agreement to the President of the Company at its offices in Bloomfield, Connecticut, within sixty (60) days of the date on which the Participant receives this Agreement.  The Participant must execute the signature page of this Agreement and a copy of Exhibit A to this Agreement.  In the event that this Agreement is executed by the Company and the Participant prior to the completion of Exhibit A, the Company shall complete Exhibit A within a reasonable time.  Unless otherwise determined by the Committee in its sole and absolute discretion and except as provided under Section 2(b) (in the case of death or Disability) or Section 6 (in the case of a Change in Control) of this Agreement, the Participant shall not be entitled to any payment under this Agreement unless the Performance Goals set forth in Exhibit A shall have been achieved. 

2.Vesting, Termination and Forfeiture.

(a)Except as otherwise provided in this Section 2 and Section 6 below, a Participant must be employed with the Company on the last day of the Performance Cycle in order to have a vested right to 

receive payment of earned amounts based on the Company’s attainment of the Performance Goals specified in Exhibit A to this Agreement.

(b)If the employment of the Participant terminates during the Performance Cycle relating to the Long-Term Performance Award because of death or Disability, then a pro rata portion of the Long-Term Performance Award shall be deemed fully vested and fully earned by such Participant (or his estate), such portion to be determined by multiplying 100% of Target (as set forth in Exhibit A) by a fraction, the numerator of which shall be the number of days from the beginning of the Performance Cycle to the date of such termination and the denominator of which shall be the total number of days during the Performance Cycle.  Such earned portion shall be paid as soon as reasonably practicable following the date of such termination.

(c)If the employment of the Participant terminates during the Performance Cycle relating to the Long-Term Performance Award because of Retirement, then the Participant shall be deemed to be vested in a pro rata portion of any payment with respect to the Long-Term Performance Award subject to such Performance Cycle, determined by multiplying such payment, calculated as if the Participant's employment or consultancy had not been terminated, by a fraction the numerator of which shall be the number of days from the beginning of the Performance Cycle to the date of such termination and the denominator of which shall be the total number of days during the Performance Cycle.

(d)If the employment of the Participant terminates during the Performance Cycle relating to the Long-Term Performance Award for any reason other than death, Disability or Retirement, then the Participant shall not be entitled to any payment with respect to the Long-Term Performance Award subject to such Performance Cycle, unless the Committee shall otherwise determine in its discretion to waive the continuing employment requirement under Section 2(a) above.

(e)As used in this Agreement, the term “Retirement” means the termination of a Participant’s employment with the Company or a Subsidiary other than for Cause (a) after attaining age 62 with at least five years of employment service or (b) after attaining age 65, the term “Disability” or “Disabled” means permanent and total disability as defined by Code Section 22(e)(3), and the term “Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor Code, and related rules, regulations and interpretations.

3.Payment.  Except as provided under Section 2(b) (in the case of death or Disability) or Section 6 (in the case of Change in Control), the vested and earned portion of the Long-Term Performance Award shall be paid in cash as soon as practicable after the end of the applicable Performance Cycle, but in no event after the September 30th immediately following such Performance Cycle, provided that the Committee may elect to pay up to one-third (1/3) of such amount in whole Shares or, at the discretion of the Committee, up to the entire amount of such earned portion may be paid in whole Shares to the extent requested by the Participant.  Any such Shares shall be valued at their Fair Market Value at the close of business on the most recent trading day preceding the date of such payment and shall be issued in uncertificated form and recorded on the shareholder records maintained by the Transfer Agent and Registrar of the Shares (the “Transfer Agent”).

4.No Employment Rights.  No provision of this Agreement shall:

(a)confer or be deemed to confer upon the Participant any right to continue in the employ of the Company or any Subsidiary or shall in any way affect the right of the Company or any Subsidiary to 

dismiss or otherwise terminate the Participant’s employment at any time for any reason with or without cause, or

(b)be construed to impose upon the Company or any Subsidiary any liability for any forfeiture of the Long-Term Performance Award which may result under this Agreement if the Participant’s employment is so terminated, or

(c)affect the Company’s right to terminate or modify any contractual relationship with the Participant if the Participant is not an employee of the Company or a Subsidiary.

5.No Liability for Business Acts or Omissions.  The Participant recognizes and agrees that the Board or the officers, agents or employees of the Company in their conduct of the business and affairs of the Company, may cause the Company to act, or to omit to act, in a manner that may, directly or indirectly, affect the amount of or the ability of the Participant to earn the Long-Term Performance Award under this Agreement.  No provision of this Agreement shall be interpreted or construed to impose any liability upon the Company, the Board or any officer, agent or employee of the Company for any effect on the Participant’s entitlement under the Long-Term Performance Award that may result, directly or indirectly, from any such action or omission.

6.Change in Control.  The Long-Term Performance Award shall be settled upon a Change in Control as provided in Section 13 of the Plan provided that the transaction or event triggering a Change in Control constitutes a “change in control event” as defined in Treasury Regulation § 1.409A-3(i)(5) .

7.Committee’s Discretion.  The Committee may, in its sole and absolute discretion, increase or decrease the amount of an award otherwise payable under this Agreement.

8.Changes in Capitalization.
(a)Neither this Agreement nor the issuance of any Shares in payment or partial payment of the Long-Term Performance Award shall affect in any way the right or power of the Company or its shareholders to make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Company’s capital structure or its business, or any merger or consolidation of the Company, or any issue of bonds, debentures, preferred or prior preference stocks ahead of or affecting the Shares or the rights thereof, or the transfer of all or any part of its assets or business, or any other corporate act or proceedings, whether of a similar character or otherwise.
(b)In the event of a recapitalization, stock split, stock dividend, divisive reorganization or other change in capitalization affecting the Shares, an appropriate adjustment will be made in respect of any Shares issued to the Participant in payment of any or all of Participant’s entitlement under the Long-Term Performance Award.

9.Tax Withholding.  The settlement of this Award is conditioned on the Participant making arrangements reasonably satisfactory to the Company for the withholding of all applicable federal, state, local or foreign taxes as may be required under applicable law.

10.Interpretation.  This Agreement shall at all times be interpreted, administered and applied in a manner consistent with the provisions of the Plan.  In the event of any inconsistency between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control and the Plan is incorporated herein by reference; provided, however, that, in the event of any inconsistency between an employment agreement (an “Employment Agreement”) between the Participant and the Company, its Subsidiaries or Affiliates, the terms of such agreement shall control.  For the avoidance of doubt, any capitalized terms used 

in either this Agreement or the Plan and an Employment Agreement shall have the meanings set forth in the Employment Agreement.  

11.Amendment; Modification; Waiver.  No provision of this Agreement may be amended, modified or waived unless such amendment, modification or waiver shall be authorized by the Committee and shall be agreed to in writing by the Participant.

12.Complete Agreement.  This Agreement contains the entire Agreement of the parties relating to the subject matter of this Agreement and supersedes any prior agreements or understandings with respect thereto.

13.Agreement Binding.  This Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns and the Participant, his heirs, devisees and legal representatives.

14.Legal Representative.  In the event of the Participant’s death or a judicial determination of his incompetence, reference in this Agreement to the Participant shall be deemed to refer to his legal representative, heirs or devisees, as the case may be.

15.Business Day.  If any event provided for in this Agreement is scheduled to take place on a day on which the Company’s corporate offices are not open for business, such event shall take place on the next succeeding day on which the Company’s corporate offices are open for business.

16.Titles.  The titles to sections or paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the title of any section or paragraph.

17.Notices.

(a)Any notice to the Company pursuant to any provision of this Agreement will be deemed to have been delivered when delivered in person to the President or Secretary of the Company, when deposited in the United States mail, addressed to the President or Secretary of the Company, at the Company’s corporate offices, when delivered to the President or Secretary of the Company by electronic mail, or when delivered to such other address as the Company may from time to time designate in writing.

(b)Any notice to the Participant pursuant to any provision of this Agreement will be deemed to have been delivered when delivered to the Participant in person, when deposited in the United States mail, addressed to the Participant at the address on the shareholder records of the Company, when delivered to the Participant by electronic mail, or when delivered to such other address as the Participant may from time to time designate in writing.

18.Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.  Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

19.Electronic Delivery.  In lieu of receiving documents in paper format, the Participant agrees, to the fullest extent permitted by law, to accept electronic delivery of any documents that the Company may 

be required to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other agreements, forms and communications) in connection with this and any other prior or future incentive award or program made or offered by the Company or its predecessors or successors.  Electronic delivery of a document to the Participant may be via a Company e-mail system or by reference to a location on a Company intranet site to which the Participant has access.

20.Compensation Recovery.  The Company may cancel, forfeit or recoup any rights or benefits of, or payments to, the Participant hereunder, including but not limited to any cash payments made, or Shares issued by, the Company following vesting of the Long-Term Performance Award under this Agreement or the proceeds from the sale of any such Shares, under any future compensation recovery policy that it may establish and maintain from time to time, to meet listing requirements that may be imposed in connection with the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise.  The Company shall delay the exercise of its rights under this Section for the period as may be required to preserve equity accounting treatment.

21.Limitation on Excess Parachute Payments.  The settlement of this Award is conditioned on the Participant making arrangements reasonably satisfactory to the Company for the withholding of all applicable federal, state, local or foreign taxes as may be required under applicable law.  The Participant shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any payment received under this Agreement.  Notwithstanding any other provision in this Agreement to the contrary, any payment or benefit received or to be received by the Participant in connection with a Change in Control or the termination of employment (whether payable under the terms of this Agreement or any other plan, arrangement or agreement with the Company or one of its Subsidiaries  (collectively, the “Payments”) that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), but only if, by reason of such reduction, the net after-tax benefit received by the Participant shall exceed the net after-tax benefit that would be received by the Participant if no such reduction was made.  Whether and how the limitation under this Section 21 is applicable shall be determined under the Section 280G Rules set forth in Exhibit B, which shall be enforceable as if set forth in this Agreement.

22.Section 409A.  To the extent required by Section 409A of the Code, all references to “termination of employment” and similar phrases for purposes of this Agreement shall be construed to require a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein).  To the extent that any payment to which the Participant becomes entitled under this Agreement due to termination of employment constitutes “nonqualified deferred compensation” subject to Section 409A of the Code and the Participant is deemed at the time of such termination of  employment to be a “specified employee” under Section 409A of the Code, then such payment shall not be made or commence until the earliest of (A) the expiration of the six (6) month and one day period measured from the date of the Participant’s termination of employment from the Company or, if earlier, the date of the Participant’s death following such termination; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to the Participant, including (without limitation) the additional twenty-percent (20% tax for which the Participant would otherwise be liable under Section 409A(a)(1)(b) of the Code in absence of such deferral.  Upon the expiration of the applicable deferral period, any payment that would have otherwise been made during that period in the absence of this Section shall be paid to the Participant or the Participant’s beneficiary in one lump sum.  For purposes of this Section 14, the term “specified employee” means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i) in accordance with the Company’s policy.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.
	
				
	PARTICIPANT
	 
	KAMAN CORPORATION
 

	 
	 
	By: 
	 

	[•]
	 
	Gregory T. Troy

	 
	 
	Senior Vice President - Human Resources & Chief Human Resources Officer

Exhibit A  

LONG-TERM PERFORMANCE PROGRAM
20__ - 20__ PERFORMANCE CYCLE
SUMMARY OF TERMS

Performance Cycle

January 1, 20__ to December 31, 20__.

Performance Goals

The Committee will consider the Company’s performance on a relative basis against the performance of the Russell 2000 index companies during the Performance Cycle using:

•Average return on total capital
•Total return to shareholders

in determining the amount to be paid to the Participant on the terms and conditions set forth below. 

Definitions of Financial Measures for the Company

The following definitions will be used in determining the Company’s performance for the financial measures.

Average return on total capital will be the simple average of total return on capital achieved in each of the ______ (__) years of the Performance Cycle.

Total return to shareholders will be calculated on a dividends reinvested basis and will measure the change in value of an investment in the Company’s Shares during the Performance Cycle.

The Committee will determine the Company’s performance with respect to each of these financial measures after adjusting for the following items:

		
	•
	the effect of changes in tax law or accounting principles;

		
	•
	the dilutive effect on earnings per share that results from any increase in the number of shares used in the calculation of diluted earnings per share attributable to any outstanding convertible debt securities and any related bond hedge and warrant transactions;

		
	•
	the effects of changes in applicable foreign currency exchange rates relating to non-U.S. denominated financial performance;

		
	•
	costs and losses associated with restructuring, business consolidations, severance, management realignments or closures of the Company or any of its subsidiaries, affiliates and product lines;

		
	•
	acquisition and divestiture due diligence and integration costs and the adverse effects of acquisitions and divestitures, including spin-offs;

		
	•
	effects of losses generated by divested operations and losses associated with discontinued business operations or product lines;

		
	•
	the impact of any transaction costs and accounting charges incurred in connection with the issuance equity or issuance of or refinancing of new or existing debt securities and facilities, including but not limited to the settlement or unwinding of existing convertible bond hedge instruments and outstanding warrants;

		
	•
	the impact of any costs and accounting charges in respect of pension curtailment adjustments 

attributable to pension expense charged to company contracts with the U.S. Government, as determined under U.S. Cost Accounting Standard 418, following the freeze of future benefit accruals under the Pension Plan;
		
	•
	charges associated with environmental matters;

		
	•
	asset write-downs or impairments, including, but not limited to, goodwill and other intangible assets;

		
	•
	new capital investments and related depreciation;

		
	•
	litigation or claim judgments or settlements including contract claim settlements with customers and suppliers; 

		
	•
	the impact of charges in connection with contract terminations, including but not limited to, write-off of inventory, tooling, equipment and non-recurring costs; 

		
	•
	any impact resulting from the delay in cash receipts relating to domestic and foreign JPF orders where there is no underlying dispute as to payment; and

		
	•
	any item of an unusual nature or of a type that indicates infrequency of occurrence, or both.

Measuring Performance of Russell 2000 Companies

In measuring the performance of the Russell 2000 companies, average return on total capital and total return to shareholders will be measured using such Russell 2000 companies data as reported in Compustat Financials published by S&P Capital IQ, or a similar external reporting source in the event that Compustat Financials should cease to be published by S&P Capital IQ.

Determination of Payment Amount

Except as set forth below, the payment amount shall be determined as follows:

		
	-
	The “Target” payment is __________ (the “Target Payment Percentage) of the Participant’s base salary as of the date of this Agreement.

		
	-
	Each of the financial measures will be measured separately and given the following weighting (expressed as a percentage of the Target payment):

		
	Average return on total capital
	50%

		
	Total return to shareholders
	50%

		
	-
	The amount payable with respect to a financial measure is based on comparing the Company’s performance to the corresponding performance of the Russell 2000 index companies, calculated as described above, as follows.

Kaman vs. Russell 2000 Companies                 % of Target Payable    
Below 25th percentile        0%
25th percentile      25%
50th percentile    100%
75th percentile & above    200%

The percent of the Target award earned for actual performance between the 25th and the 50th percentile and between the 50th and 75th percentile will be determined on a straight-line interpolation.

Notwithstanding the foregoing, the percentage of Target payable with respect to any particular financial measure calculated above shall be capped at 150% if the Company’s performance with 

respect to that particular financial measure is less than zero.

Nothing in this Exhibit A shall preclude the Committee from increasing or decreasing the payment that would otherwise be payable as permitted under the Plan due to attaining the Performance Goals. 

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Exhibit A to the Agreement to be executed as of February __, 2018.

	
				
	PARTICIPANT
	 
	KAMAN CORPORATION
 

	 
	 
	By: 
	 

	[•]
	 
	Gregory T. Troy

	 
	 
	Senior Vice President - Human Resources & Chief Human Resources Officer

Exhibit B -Section 280G Rules

The following rules shall apply for purposes of determining whether and how the limitations provided under Section 21 are applicable to the Participant.  

1.  The “net after-tax benefit” shall mean (i) the Payments (as defined in Section 21) which the Participant receives or is then entitled to receive from the Company or a Subsidiary or Affiliate that would constitute “parachute payments” within the meaning of Section 280G of the Code, less (ii) the amount of all federal, state and local income and employment taxes payable by the Participant with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to the Participant (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in (i) above.  

2.  All determinations under Section 21 of this Agreement and this Exhibit B will be made by an accounting firm or law firm that is selected for this purpose by the Company’s Chief Executive Officer prior to a Change in Control (the “280G Firm”).  All fees and expenses of the 280G Firm shall be borne by the Company.  The Company will direct the 280G Firm to submit any determination it makes under Section 21 of this Agreement and this Exhibit B and detailed supporting calculations to both the Participant and the Company as soon as reasonably practicable.  

3.  If the 280G Firm determines that one or more reductions are required under Section 21 of this Agreement, the 280G Firm shall also determine which Payments shall be reduced (first from cash payments and then from non-cash benefits, in each such case first from amounts not subject to Section 409A of the Code and then from amounts subject to Section 409A of the Code, with the Payments that otherwise would be made last in time reduced first)  to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code, and the Company shall pay such reduced amount to the Participant.  

4.  As a result of the uncertainty in the application of Section 280G at the time that the 280G Firm makes its determinations under this Section, it is possible that amounts will have been paid or distributed to the Participant that should not have been paid or distributed (collectively, the “Overpayments”), or that additional amounts should be paid or distributed to the Participant (collectively, the “Underpayments”).  If the 280G Firm determines, based on either the assertion of a deficiency by the Internal Revenue Service against the Company or the Participant, which assertion the 280G Firm believes has a high probability of success or controlling precedent or substantial authority, that an Overpayment has been made, the Participant must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no amount will be payable by the Participant to the Company unless, and then only to the extent that, the deemed loan and payment would either reduce the amount on which the Participant is subject to tax under Section 4999 of the Code or generate a refund of tax imposed under Section 4999 of the Code.  If the 280G Firm determines, based upon controlling precedent or substantial authority, that an Underpayment has occurred, the 280G Firm will notify the Participant and the Company of that determination and the amount of that Underpayment will be paid to the Participant promptly by the Company.  

5.  The Participant will provide the 280G Firm access to, and copies of, any books, records, and documents in the Participant’s possession as reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by Section 21 of this Agreement and this Exhibit B.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]